Vir Biotechnology (VIR) has made headlines as Chief Financial Officer Jason O’Byrne announced his resignation, effective August 3, 2026, with Brent Sabatini stepping in as the interim principal financial officer. The stock has faced recent declines, falling 9.41% over the past month and 13.40% over the past three months, despite a significant year-to-date return of 45.79%. Analysts suggest that the shares are undervalued with a fair price target of $21.56, compared to the current price of $8.66, highlighting a substantial gap influenced by anticipated growth and profit margins. However, potential setbacks in the company’s unproven therapies could jeopardize this optimistic outlook.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://finance.yahoo.com/markets/stocks/articles/vir-biotechnology-vir-could-60-001406156.html
